|

Autoimmunity After Checkpoint Blockade

RECRUITINGSponsored by Abramson Cancer Center at Penn Medicine
Actively Recruiting
SponsorAbramson Cancer Center at Penn Medicine
Started2020-02-24
Est. completion2026-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT04119713

Summary

The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* A diagnosis of cancer and prescription for a checkpoint inhibitor

Exclusion Criteria:

* Any subjects not willing or able to give consent
* Children under the age of 18
* A history of transplant

Conditions4

AutoimmunityCancerImmunotoxicityOncology

Locations1 site

University of Pennsylvania - Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
Kyra J Sacksith

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.